The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance
Open accessAbstract
OBJECTIVE—Defects in glucagon-like peptide 1 (GLP-1) secretion have been reported in some patients with type 2 diabetes after meal ingestion. We addressed the following questions: 1) Is the quantitative impairment in GLP-1 levels different after mixed meal or isolated glucose ingestion? 2) Which endogenous factors are associated with the concentrations of GLP-1? In particular, do elevated fasting glucose or glucagon levels diminish GLP-1 responses? RESEARCH DESIGN AND METHODS—Seventeen patients with mild type 2 diabetes, 17 subjects with impaired glucose tolerance, and 14 matched control subjects participated in an oral glucose tolerance test (75 g) and a mixed meal challenge (820 kcal), both carried out over 240 min on separate occasions. Plasma levels of glucose, insulin, C-peptide, glucagon, triglycerides, free fatty acids (FFAs), gastric inhibitory polypeptide (GIP), and GLP-1 were determined. RESULTS—GIP and GLP-1 levels increased significantly in both experiments (P < 0.0001). In patients with type 2 diabetes, the initial GIP response was exaggerated compared with control subjects after mixed meal (P < 0.001) but not after oral glucose ingestion (P = 0.98). GLP-1 levels were similar in all three groups in both experiments. GIP responses were 186 ± 17% higher after mixed meal ingestion than after the oral glucose load (P < 0.0001), whereas GLP-1 levels were similar in both experiments. There was a strong negative association between fasting glucagon and integrated FFA levels and subsequent GLP-1 concentrations. In contrast, fasting FFA and integrated glucagon levels after glucose or meal ingestion and female sex were positively related to GLP-1 concentrations. Incretin levels were unrelated to measures of glucose control or insulin secretion. CONCLUSIONS—Deteriorations in glucose homeostasis can develop in the absence of any impairment in GIP or GLP-1 levels. This suggests that the defects in GLP-1 concentrations previously described in patients with long-standing type 2 diabetes are likely secondary to other hormonal and metabolic alterations, such as hyperglucagonemia. GIP and GLP-1 concentrations appear to be regulated by different factors and are independent of each other.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Self-citationNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307
Self-citationDipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
Mentlein, R. (1999) · Regulatory Peptides · doi:10.1016/s0167-0115(99)00089-0 · Cited by 1,272
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Self-citationNAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Self-citationCreutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Abnormal Alpha-Cell Function in Diabetes: Response to Carbohydrate and Protein Ingestion
Müller, W. A., Faloona, G. R., Aguilar-Parada, E., & Unger, R. H. (1970) · New England Journal of Medicine · doi:10.1056/nejm197007162830301 · Cited by 626
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Self-citationNauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Self-citationØRSKOV, C., HOLST, J. J., KNUHTSEN, S., BALDISSERA, F. G. A., POULSEN, S. S., & NIELSEN, O. V. (1986) · Endocrinology · doi:10.1210/endo-119-4-1467 · Cited by 482
Self-citationRelationship between oral glucose tolerance and gastric emptying in normal healthy subjects
Horowitz, M., Edelbroek, M. A. L., Wishart, J. M., & Straathof, J. W. (1993) · Diabetologia · doi:10.1007/bf00400362 · Cited by 469
Deacon, C. F., Nauck, M. A., Meier, J., Hücking, K., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.10.6855 · Cited by 401
Self-citationØRSKOV, C., HOLST, J. J., & NIELSEN, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 396
Self-citationGastric and oesophageal emptying in patients with Type 2 (non-insulin-dependent) diabetes mellitus
Horowitz, M., Harding, P. E., Maddox, A. F., Wishart, J. M., Akkermans, L. M. A., Chatterton, B. E., & Shearman, D. J. C. (1989) · Diabetologia · doi:10.1007/bf00265086 · Cited by 392
Orskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Self-citationMeier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Self-citationInsulin secretion in diabetes mellitus
Pfeifer, M. A., Halter, J. B., & Porte, D. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90579-9 · Cited by 367
Gentilcore, D., Chaikomin, R., Jones, K. L., Russo, A., Feinle-Bisset, C., Wishart, J. M., Rayner, C. K., & Horowitz, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2644 · Cited by 351
Reduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
Self-citationContribution of Abnormal Muscle and Liver Glucose Metabolism to Postprandial Hyperglycemia in NIDDM
Mitrakou, A., Kelley, D., Veneman, T., Jenssen, T., Pangburn, T., Reilly, J., & Gerich, J. (1990) · Diabetes · doi:10.2337/diab.39.11.1381 · Cited by 317
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationGastric emptying in diabetes: clinical significance and treatment
Horowitz, M., O’Donovan, D., Jones, K. L., Feinle, C., Rayner, C. K., & Samsom, M. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00658.x · Cited by 308
Deacon, C. F. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.10.3575 · Cited by 301
Glucagon-like peptide 1(GLP-1) in biology and pathology
Meier, J. J., & Nauck, M. A. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.538 · Cited by 288
Self-citationNew developments in the incretin concept
Creutzfeldt, W., & Ebert, R. (1985) · Diabetologia · doi:10.1007/bf00281990 · Cited by 279
Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276
Self-citationMeier, J. J., Nauck, M. A., Pott, A., Heinze, K., Goetze, O., Bulut, K., Schmidt, W. E., Gallwitz, B., & Holst, J. J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.10.004 · Cited by 266
Self-citationMeier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 230
Self-citationGastric Inhibitory Polypeptide: the neglected incretin revisited
Meier, J. J., Nauck, M. A., Schmidt, W. E., & Gallwitz, B. (2002) · Regulatory Peptides · doi:10.1016/s0167-0115(02)00039-3 · Cited by 226
Self-citationStructure, measurement, and secretion of human glucagon-like peptide-2
Hartmann, B., Johnsen, A. H., Ørskov, C., Adelhorst, K., Thim, L., & Holst, J. J. (2000) · Peptides · doi:10.1016/s0196-9781(99)00176-x · Cited by 221
Self-citationIn Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans1
Hartmann, B., Harr, M. B., Jeppesen, P. B., Wojdemann, M., Deacon, C. F., Mortensen, P. B., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6717 · Cited by 191
Self-citationRyskjær, J., Deacon, C. F., Carr, R. D., Krarup, T., Madsbad, S., Holst, J., & Vilsbøll, T. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02221 · Cited by 181
Self-citationHolst, J. J. (1982) · Biochemical Journal · doi:10.1042/bj2070381 · Cited by 176
Self-citationGastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Nauck, M. A., Baller, B., & Meier, J. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s190 · Cited by 163
Self-citationPEDERSON, R. A., & BROWN, J. C. (1978) · Endocrinology · doi:10.1210/endo-103-2-610 · Cited by 156
Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137
Self-citationHypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus
Ross, S. A., Brown, J. C., & Dupré, J. (1977) · Diabetes · doi:10.2337/diab.26.6.525 · Cited by 135
Krarup, T., Saurbrey, N., Moody, A. J., Kühl, C., & Madsbad, S. (1987) · Metabolism · doi:10.1016/0026-0495(87)90153-3 · Cited by 128
Gastric inhibitory polypeptide does not inhibit gastric emptying in humans
Meier, J. J., Goetze, O., Anstipp, J., Hagemann, D., Holst, J. J., Schmidt, W. E., Gallwitz, B., & Nauck, M. A. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00499.2003 · Cited by 126
Self-citationThe pathogenesis of NIDDM involves a defective expression of the GIP receptor
Holst, J. J., Gromada, J., & Nauck, M. A. (1997) · Diabetologia · doi:10.1007/s001250050779 · Cited by 116
Self-citationIncretin Effect Due to Increased Secretion and Decreased Clearance of Insulin in Normal Humans
Shuster, L. T., Go, V. L. W., Rizza, R. A., O’Brien, P. C., & Service, F. J. (1988) · Diabetes · doi:10.2337/diab.37.2.200 · Cited by 108
Immunoreactive gastric inhibitory polypeptide.
Krarup, T. (1988) · Endocrine reviews · doi:10.1210/edrv-9-1-122 · Cited by 105
Meier, J. J., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Nauck, M. A. (2007) · Diabetologia · doi:10.1007/s00125-007-0598-z · Cited by 92
Self-citationJones, I. R., Owens, D. R., Luzio, S. D., Williams, S. E. I., & Hayes, T. M. (1989) · Diabetologia · doi:10.1007/bf00274255 · Cited by 91
Nyholm, B., Walker, M., Gravholt, C. H., Shearing, P. A., Sturis, J., Alberti, K. G. M. M., Holst, J. J., & Schmitz, O. (1999) · Diabetologia · doi:10.1007/s001250051444 · Cited by 90
Self-citationIn Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans
Hartmann, B. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2884 · Cited by 84
Alvarado, J. A., Betanzos, A., Franse-Carman, L., Chen, J., & González‐Mariscal, L. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00108.2003 · Cited by 83
Meier, J. J., Gallwitz, B., Askenas, M., Vollmer, K., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1863-7 · Cited by 78
Self-citationGlucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Meier, J. J., & Nauck, M. A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.007 · Cited by 76
Self-citationde Heer, J., Pedersen, J., Ørskov, C., & Holst, J. J. (2007) · Diabetologia · doi:10.1007/s00125-007-0761-6 · Cited by 69
Self-citationTseng, C., Boylan, M. O., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.270.4.e661 · Cited by 56
Holst, J. J. (1983) · Regulatory Peptides · doi:10.1016/0167-0115(83)90766-8 · Cited by 25
Self-citation
Cited by
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
“Postprandial GIP levels are approximately 4-fold higher compared to GLP-1 under normal physiological conditions [15].”
BackgroundThe role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Pancreatic β-Cell Electrical Activity and Insulin Secretion: Of Mice and Men
Rorsman, P., & Ashcroft, F. M. (2018) · Physiological Reviews · doi:10.1152/physrev.00008.2017 · Cited by 793
GIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Metadata
- Authors
- Vollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-03-01
- Volume
- 57
- Issue
- 3
- Pages
- 678-687
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2135854640
- Cited by
- 356
- References
- 56
- FWCI
- 15.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.